Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • For Subscribers
    • For Advertisers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • For Subscribers
    • For Advertisers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleArticle

Interspecies Differences in the Cardiac Negative Inotropic Effects of β3-Adrenoceptor Agonists

Chantal Gauthier, Geneviève Tavernier, Jean-Noël Trochu, Véronique Leblais, Karine Laurent, Dominique Langin, Denis Escande and Hervé Le Marec
Journal of Pharmacology and Experimental Therapeutics August 1999, 290 (2) 687-693;
Chantal Gauthier
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Geneviève Tavernier
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean-Noël Trochu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Véronique Leblais
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karine Laurent
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dominique Langin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Denis Escande
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hervé Le Marec
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The aim of the present study was to compare the effects of three preferential (BRL 37344, SR 58611, CL 316 243) and a partial (CGP 12177) β-adrenoceptor (β3-AR) agonists on the contractility of ventricular strips sampled from various mammalian species including humans. In the human heart, all β3-AR agonists tested decreased contractility by 40 to 60% below control with an order of potency: BRL 37344 > CL 316 243 = SR 58611 ≫ CGP 12177. In the dog, the negative inotropic effects produced by β3-AR stimulation were less pronounced than in humans, ≈30% below control. The order of potency of β3-AR agonists was CGP 12177 > BRL 37344 = SR 58611 ≫ CL 316 243; i.e., very different from that observed in humans. In rat, only BRL 37344 was efficient to decrease contractility. In guinea pig, only CL 316 243 significantly reduced peak tension. In both species, the reduction in peak tension did not exceed 20 to 30%. Finally, in the ferret, none of the agonists tested induced a negative inotropic effect. In dog, the negative inotropic effects of CGP 12177 were not modified by nadolol, but were abolished by bupranolol, a β1–3-AR. β3-AR transcripts were detected in the dog but not in the rat ventricle by using a reverse transcription-polymerase chain reaction assay. We conclude that cardiac negative inotropic effects related to β3-AR agonist stimulation vary markedly depending on the species. A comparable interspecies variation previously has been reported concerning the lipolytic effects of β3-AR agonist stimulation. Our study demonstrates that the pharmacological profile of a β3-AR agonist on the human myocardium cannot be extrapolated from usual animal models.

Footnotes

  • Send reprint requests to: Dr. Chantal Gauthier, Laboratoire de Physiopathologie et Pharmacologie Cellulaires et Moléculaires, Institut National de la Santé et de la Recherche Médicale, CJF 96–01, Hôtel Dieu, 1 place Alexis Ricordeau, 44093 Nantes Cedex 1, France. E-mail:chantal.gauthier{at}sante.univ-nantes.fr

  • ↵1 This work was supported by grants from Institut National de la Santé et de la Recherche Médicale, the Association de Recherche en Physiologie et Pharmacologie (ARPP), and the Fédération Française de Cardiologie.

  • Abbreviations:
    AR
    adrenoceptor
    CGP 12177
    4-[3-t-butylamino-2-hydroxypropoxy]benzimidazol-2-one
    SR 58611
    (N[2s)7-carb-ethoxymethoxy-1,2,3,4-tetra-hydronaphth]-(2r)-2-hydroxy-2(3-chlorophenyl) ethamine hydrochloride
    CL 316 243
    5-(2-{[2-(3-chlorophenyl)-2-hydroxyethyl]-amino}propyl)-1,3-benzodioxole-2,2-dicarboxylate
    BRL 37344
    4-[−[2-hydroxy-(3-chlorophenyl)ethyl-amino]propyl]phenoxyacetate
    RT-PCR
    reverse transcription-polymerase chain reaction
    • Received May 26, 1998.
    • Accepted March 29, 1999.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

Log in using your username and password

Forgot your user name or password?

Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$35.00

Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.

PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 290 (2)
Journal of Pharmacology and Experimental Therapeutics
Vol. 290, Issue 2
1 Aug 1999
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Interspecies Differences in the Cardiac Negative Inotropic Effects of β3-Adrenoceptor Agonists
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
Citation Tools
Research ArticleArticle

Interspecies Differences in the Cardiac Negative Inotropic Effects of β3-Adrenoceptor Agonists

Chantal Gauthier, Geneviève Tavernier, Jean-Noël Trochu, Véronique Leblais, Karine Laurent, Dominique Langin, Denis Escande and Hervé Le Marec
Journal of Pharmacology and Experimental Therapeutics August 1, 1999, 290 (2) 687-693;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleArticle

Interspecies Differences in the Cardiac Negative Inotropic Effects of β3-Adrenoceptor Agonists

Chantal Gauthier, Geneviève Tavernier, Jean-Noël Trochu, Véronique Leblais, Karine Laurent, Dominique Langin, Denis Escande and Hervé Le Marec
Journal of Pharmacology and Experimental Therapeutics August 1, 1999, 290 (2) 687-693;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • CRV431 Decreases Liver Fibrosis and Tumor Development
  • Prolonged Inhibition ofO 6-Methylguanine DNA Methyltransferase in Human Tumor Cells by O 6-Benzylguanine In Vitro and In Vivo
  • Reduction of 5-Hydroxytryptamine (5-HT)1A-Mediated Temperature and Neuroendocrine Responses and 5-HT1A Binding Sites in 5-HT Transporter Knockout Mice
Show more Article

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2019 by the American Society for Pharmacology and Experimental Therapeutics